News & Updates

A Hong Kong study demonstrates vertical transfer of antibodies against acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to babies whose mothers have recovered from coronavirus disease 2019 (COVID-19).

Researchers from the University of Hong Kong (HKU) have developed a dry powder formulation of tamibaroterone, which displays broad-spectrum antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), and pandemic 2009 influenza A virus (H1N1), when delivered intranasally or through inhalation in mouse and hamster models.

An infusion of convalescent plasma, obtained via blood donation from individuals who have recovered from COVID-19, did not prevent disease progression in high-risk outpatients who presented within 7 days of COVID-19 symptom onset, results of the phase III US-based SIREN-C3PO* study showed.

A wearable chest patch device can continuously monitor vital signs in patients with the coronavirus disease 2019 (COVID-19), facilitating the early detection of cardiovascular deterioration, according to a recent study.

Late intubation compounds the risk of death among coronavirus disease 2019 (COVID-19) patients on mechanical intubation due to respiratory insufficiency, a recent study has found.

The antiviral monoclonal antibodies casirivimab-imdevimab appear to reduce the risk of hospitalization in patients with nonsevere COVID-19, as do bamlanivimab, bamlanivimab-etesevimab, and sotrovimab, according to the results of a systematic review and meta-analysis.

A manikin study has shown that use of the standard face shield is not enough to protect against droplet dispersion during oropharyngeal COVID-19 swabs, but the SG Shield results in significant reduction of droplet contamination to the swab provider’s face and chest.